- “Prevention of Atrial Fibrillation by Bucindolol is Completely Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism.” (Expanded Panel Discussion – EPD.400.03 – Atrial Fibrillation: Novel Insights into Mechanisms; Wednesday, November 16, 2011, from 9:00 a.m. to 11:45 a.m. Eastern).
- “Is New Onset Atrial Fibrillation a Surrogate Marker for Heart Failure Progression?” (Abstract Oral Session – AOS.516.01 – Ventricular Function/Hemodynamics and Biomarkers; Wednesday, November 16, 2011, from 2:00 p.m. to 5:10 p.m. Eastern).
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, announced today that two Gencaro (bucindolol hydrochloride) abstracts have been selected for oral presentation at the American Heart Association’s Scientific Sessions 2011, being held November 12-16, 2011 in Orlando, Florida. The abstracts present atrial fibrillation data from the pivotal Phase 3 BEST trial of Gencaro. Dr. Ryan Aleong, Assistant Professor of Medicine, Cardiology, Director of Implanted Cardiac Device Clinic, University of Colorado Hospital, and Interim Director of Arrhythmia Services at Denver Health Medical Center, is scheduled to present both abstracts: